FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3217503653> ?p ?o ?g. }

• W3217503653 endingPage "6057" @default.
• W3217503653 startingPage "6057" @default.
• W3217503653 abstract "Clear cell sarcoma (CCSA) is characterized by a chromosomal translocation leading to EWSR1 rearrangement, resulting in aberrant transcription of multiple genes, including MET. The EORTC 90101 phase II trial evaluated the MET inhibitor crizotinib in CCSA but resulted in only sporadic responses. We performed an in-depth histopathological and molecular analysis of archival CCSA samples to identify alterations potentially relevant for the treatment outcome. Immunohistochemical characterization of MET signaling was performed using a tissue microarray constructed from 32 CCSA cases. The DNA from 24 available tumor specimens was analyzed by low-coverage whole-genome sequencing and whole-exome sequencing for the detection of recurrent copy number alterations (CNAs) and mutations. A pathway enrichment analysis was performed to identify the pathways relevant for CCSA tumorigenesis. Kaplan-Meier estimates and Fisher's exact test were used to correlate the molecular findings with the clinical features related to crizotinib treatment, aiming to assess a potential association with the outcomes. The histopathological analysis showed the absence of a MET ligand and MET activation, with the presence of MET itself in most of cases. However, the expression/activation of MET downstream molecules was frequently observed, suggesting the role of other receptors in CCSA signal transduction. Using sequencing, we detected a number of CNAs at the chromosomal arm and region levels. The most common alteration was a gain of 8q24.21, observed in 83% of the cases. The loss of chromosomes 9q and 12q24 was associated with shorter survival. Based on exome sequencing, 40 cancer-associated genes were found to be mutated in more than one sample, with SRGAP3 and KMT2D as the most common alterations (each in four cases). The mutated genes encoded proteins were mainly involved in receptor tyrosine kinase signaling, polymerase-II transcription, DNA damage repair, SUMOylation and chromatin organization. Disruption in chromatin organization was correlated with longer progression-free survival in patients receiving crizotinib. Conclusions: The infrequent activation of MET may explain the lack of response to crizotinib observed in the majority of cases in the clinical trial. Our work describes the molecular heterogeneity in CCSA and provides further insight into the biology of this ultra-rare malignancy, which may potentially lead to better therapeutic approaches for CCSA." @default.
• W3217503653 created "2021-12-06" @default.
• W3217503653 creator A5015197719 @default.
• W3217503653 creator A5021550191 @default.
• W3217503653 creator A5041905625 @default.
• W3217503653 creator A5042202815 @default.
• W3217503653 creator A5055506828 @default.
• W3217503653 creator A5060954086 @default.
• W3217503653 creator A5074975947 @default.
• W3217503653 creator A5078760536 @default.
• W3217503653 creator A5081418446 @default.
• W3217503653 creator A5086102127 @default.
• W3217503653 creator A5091460068 @default.
• W3217503653 date "2021-12-01" @default.
• W3217503653 modified "2023-10-14" @default.
• W3217503653 title "Histopathological and Molecular Profiling of Clear Cell Sarcoma and Correlation with Response to Crizotinib: An Exploratory Study Related to EORTC 90101 “CREATE” Trial" @default.
• W3217503653 cites W1563940013 @default.
• W3217503653 cites W1970894458 @default.
• W3217503653 cites W1973728202 @default.
• W3217503653 cites W1973905761 @default.
• W3217503653 cites W1982669668 @default.
• W3217503653 cites W1983035953 @default.
• W3217503653 cites W1985850253 @default.
• W3217503653 cites W1992392601 @default.
• W3217503653 cites W1993160539 @default.
• W3217503653 cites W1997391548 @default.
• W3217503653 cites W2001070269 @default.
• W3217503653 cites W2006288875 @default.
• W3217503653 cites W2011721336 @default.
• W3217503653 cites W2032981041 @default.
• W3217503653 cites W2043730237 @default.
• W3217503653 cites W2053423813 @default.
• W3217503653 cites W2065240200 @default.
• W3217503653 cites W2083914403 @default.
• W3217503653 cites W2084020418 @default.
• W3217503653 cites W2089139236 @default.
• W3217503653 cites W2097948046 @default.
• W3217503653 cites W2111842868 @default.
• W3217503653 cites W2117151547 @default.
• W3217503653 cites W2124954099 @default.
• W3217503653 cites W2125398987 @default.
• W3217503653 cites W2125636389 @default.
• W3217503653 cites W2130470264 @default.
• W3217503653 cites W2132683512 @default.
• W3217503653 cites W2149441684 @default.
• W3217503653 cites W2157852151 @default.
• W3217503653 cites W2169500410 @default.
• W3217503653 cites W2280275403 @default.
• W3217503653 cites W2297645879 @default.
• W3217503653 cites W2308285449 @default.
• W3217503653 cites W2373606074 @default.
• W3217503653 cites W2410682694 @default.
• W3217503653 cites W2475363814 @default.
• W3217503653 cites W2549863932 @default.
• W3217503653 cites W2566081648 @default.
• W3217503653 cites W2609652695 @default.
• W3217503653 cites W2611497676 @default.
• W3217503653 cites W2613362156 @default.
• W3217503653 cites W2727134083 @default.
• W3217503653 cites W2728031786 @default.
• W3217503653 cites W2755514319 @default.
• W3217503653 cites W2795073885 @default.
• W3217503653 cites W2886334360 @default.
• W3217503653 cites W2894573839 @default.
• W3217503653 cites W2910111050 @default.
• W3217503653 cites W2949857618 @default.
• W3217503653 cites W2952629135 @default.
• W3217503653 cites W2967208159 @default.
• W3217503653 cites W2982546313 @default.
• W3217503653 cites W2990466515 @default.
• W3217503653 cites W2995570957 @default.
• W3217503653 cites W3021706537 @default.
• W3217503653 cites W3107626709 @default.
• W3217503653 cites W3136349265 @default.
• W3217503653 cites W3143315980 @default.
• W3217503653 cites W4245967957 @default.
• W3217503653 doi "https://doi.org/10.3390/cancers13236057" @default.
• W3217503653 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34885165" @default.
• W3217503653 hasPublicationYear "2021" @default.
• W3217503653 type Work @default.
• W3217503653 sameAs 3217503653 @default.
• W3217503653 citedByCount "7" @default.
• W3217503653 countsByYear W32175036532022 @default.
• W3217503653 countsByYear W32175036532023 @default.
• W3217503653 crossrefType "journal-article" @default.
• W3217503653 hasAuthorship W3217503653A5015197719 @default.
• W3217503653 hasAuthorship W3217503653A5021550191 @default.
• W3217503653 hasAuthorship W3217503653A5041905625 @default.
• W3217503653 hasAuthorship W3217503653A5042202815 @default.
• W3217503653 hasAuthorship W3217503653A5055506828 @default.
• W3217503653 hasAuthorship W3217503653A5060954086 @default.
• W3217503653 hasAuthorship W3217503653A5074975947 @default.
• W3217503653 hasAuthorship W3217503653A5078760536 @default.
• W3217503653 hasAuthorship W3217503653A5081418446 @default.
• W3217503653 hasAuthorship W3217503653A5086102127 @default.
• W3217503653 hasAuthorship W3217503653A5091460068 @default.
• W3217503653 hasBestOaLocation W32175036531 @default.
• W3217503653 hasConcept C104317684 @default.

• next